
简介:
- 作者: Kan Yang, Yuhan Shi, Xiujuan Du, Jincheng Wang, Yuefang Zhang, Shifang Shan, Yiting Yuan, Ruoqing Wang, Chenhuan Zhou, Yuting Liu, Zilin Cai, Yanzhi Wang, Liu Fan, Huatai Xu, Juehua Yu, Jinke Cheng, Fei Li, Zilong Qiu
- 杂志: Cell Reports
- Doi: https://www.doi.org/10.1016/j.celrep.2021.109939
- 出版日期: 2021 Nov 2
论文中使用的产品/服务
Quotation shows PackGene:AAV9-hSyn-EGFP (Serotype 9, titer 8.5x 10^14 vg/ mL), AAV9-hSyn-SENP1-EGFP (Serotype 9, titer 4.1x 10^13 vg/mL), AAV9-hSyn-SENP1-C603S-EGFP (Serotype 9, titer 4.1x10^13 vg/mL), AAV9-hSyn-FMRP-EGFP (Serotype 9, titer 4x10^13 vg/mL) and AAV9-hSyn-FMRP-K88RK130R-EGFP (Serotype 9, titer 6.2x10^13 vg/mL) were purchased from Institute of Neuroscience Gene Editing Core and PackGene Bioscience, Co, Guangzhou.
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:C57BL/6N mice
摘要
Autism spectrum disorder (ASD) is a highly heritable neurodevelopmental disorder, causing defects of social interaction and repetitive behaviors. Here, we identify a de novo heterozygous gene-truncating mutation of the Sentrin-specific peptidase1 (SENP1) gene in people with ASD without neurodevelopmental delay. We find that Senp1+/− mice exhibit core autistic-like symptoms such as social deficits and repetitive behaviors but normal learning and memory ability. Moreover, we find that inhibitory and excitatory synaptic functions are severely affected in the retrosplenial agranular (RSA) cortex of Senp1+/− mice. Lack of Senp1 leads to increased SUMOylation and degradation of fragile X mental retardation protein (FMRP), also implicated in syndromic ASD. Importantly, re-introducing SENP1 or FMRP specifically in RSA fully rescues the defects of synaptic function and autistic-like symptoms of Senp1+/− mice. Together, these results demonstrate that disruption of the SENP1-FMRP regulatory axis in the RSA causes autistic symptoms, providing a candidate region for ASD pathophysiology.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
